Ryan J Winstead
Overview
Explore the profile of Ryan J Winstead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winstead R, Kumar D, Brown A, Yakubu I, Song C, Thacker L, et al.
Transpl Infect Dis
. 2021 Jan;
23(4):e13570.
PMID: 33469975
Background: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a new agent approved for CMV...
2.
Winstead R, Demehin M, Yakubu I, Song C, Brown A, Levy M, et al.
Clin Transplant
. 2020 Jan;
34(3):e13791.
PMID: 31991491
No abstract available.
3.
Winstead R, Waldman G, Autry E, Evans R, Schadler A, Kays L, et al.
Prog Transplant
. 2019 Jun;
29(3):220-224.
PMID: 31159656
Introduction: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of . Research Question:...
4.
Winstead R, Pandya K, Flynn J, Davis G, Sieg A, Guglin M, et al.
J Thromb Thrombolysis
. 2018 Mar;
45(3):452-456.
PMID: 29508176
Recombinant, activated factor VIIa (rFVIIa) is used during cardiac surgeries to mitigate refractory coagulopathic bleeding. The purpose of this study was to examine whether rFVIIa use in orthotopic heart transplant...
5.
Iasella C, Winstead R, Moore C, Johnson B, Feinberg A, Morrell M, et al.
Transplantation
. 2017 Jul;
102(1):171-177.
PMID: 28691954
Background: Traditional immunosuppressive regimens (ISR) used in lung transplantation rely on calcineurin inhibitors (CNI) that occasionally cause severe adverse reactions necessitating discontinuation. Belatacept is a novel costimulation antagonist approved for...